Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethionamide sulfoxide is the major active metabolite of ethionamide, a second-line antitubercular agent. It is formed via hepatic metabolism and possesses antibacterial activity against Mycobacterium tuberculosis. Ethionamide sulfoxide contributes to the bacteriostatic and potentially bactericidal effects of ethionamide by inhibiting mycolic acid synthesis, thereby interfering with cell wall formation in mycobacteria. The metabolite is notable for retaining the antimicrobial properties of the parent drug and is integral to ethionamide’s pharmacologic profile[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethionamide sulfoxide.